chartexchange

Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting

GlobeNewswire Inc. | Nov 4, 2026 9:00 AM EST

-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations, new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) --

Read original article